Key facts
- WaveClear Vascular’s last known valuation is $3.1M (Oct 2020).
- It has raised $5.5M; the latest was Later Stage VC ($3.5M) in Dec 2025.
- Notable investors include MedTech Innovator, Ben Franklin Technology Partners of Central and Northern Pennsylvania, Hunniwell Lake Ventures, LifeX Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for WaveClear Vascular
- ·The full record, as it builds
Funding rounds
No funding rounds for WaveClear Vascular are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About WaveClear Vascular
Developer of ultrasonic therapeutic devices designed to combat vascular diseases. The company's devices utilize the piezoelectric effect to generate ultrasonic energy in wires to clear partial and total occlusions of the peripheral vasculature, enabling physicians to safely disintegrate blood clots in a single-session treatment without damaging the blood vessel.
- Sector
- Healthcare
- HQ
- Erie, PA, United States
- Founded
- 2020
- Employees
- 3
- Website
- waveclear.com/
- Ownership
- Privately Held (backing)
WaveClear Vascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in WaveClear Vascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on WaveClear Vascular in its N-PORT filings yet. We sweep new filings monthly.